clinical_symposium_300x300
Description

Intrathecal Baclofen Therapy (ITB) has been FDA approved for over 20 years, yet there are many misunderstandings about what it does and how it is managed. It is not infrequent that a patient has a positive trial but does not go on to receive the definitive therapy, because of misinterpretation of the test/trial. Botulinum toxins provide a focal, generally well tolerated treatment for spasticity and dystonia, regardless of etiology, though the indications may not be well understood in the context of function and the timing for interventions. With the use of botulinum toxin injections for more focal functional considerations, the need for therapy interventions may not be appreciated whether the patient presents with new or more chronic functional limitations. These and other considerations can lead to greater limitations in functional recovery and limiting of potential. This course will address many misconceptions about both of these interventions and address considerations in maximizing their effectiveness. Clinical scenarios and ARS will be used to engage the audience

Learning Objectives

  • Understand factors that can affect interpretation of an Intrathecal Baclofen Trial.
  • Discuss considerations of dosing botulinum toxins and goal setting in the current healthcare environment.
  • Develop a plan of care for treating spasticity that includes consideration of traditional therapies in the acute and chronic patient.
Tags